
    
      The secondary objective of the protocol assessed the engraftment of donor mesenchymal cells
      and their ability to increase the synthesis of normal type I procollagen relative to the
      synthesis of mutated type I procollagen and to assess whether BMT improves the bone structure
      and the clinical condition of these patients with OI.
    
  